Funded Startups in Del Mar
Among the eight most recent Del Mar-funded entries, the largest disclosed round is Antiva Biosciences’ $53M (Series E, 2023-04-27), which is only one of tw…
Among the eight most recent Del Mar-funded entries, the largest disclosed round is Antiva Biosciences’ $53M (Series E, 2023-04-27), which is only one of two rounds above $20M. By contrast, the remaining large figures sit in a mid-to-high single-digit or sub-$20M range, including Turnout’s $21M (Seed, 2025-09-16) and Lenz Therapeutics’ $49M (Series Unknown, 2022-11-22), while several others are much smaller, such as TradeSun at $100K (2020-12-10). The list also clusters in time: six of eight rounds fall between 2022-03-08 and 2023-04-27, with a second, smaller edge farther back in 2020 (2020-07-21 to 2020-12-10). Sector-wise, biotechnology is the most repeated theme (3 of 8), and “Series Unknown” appears in 3 of 8 entries (SAIL Fusion 2023-04-13; Lenz Therapeutics 2022-11-22; Humetrix 2022-05-05; CeleCor Therapeutics 2022-03-08). Dates span 2020-07-21 (Selva Therapeutics) through 2025-09-16 (Turnout), with the most recent entry in 2025.
Most recent rounds
8 shownRelated listings
Frequently asked
What’s the largest disclosed Del Mar round in this set, and how does it compare to the rest of the disclosed amounts?
Antiva Biosciences’ $53M on 2023-04-27 (Series E) is the largest disclosed amount, and it’s closely followed by Lenz Therapeutics’ $49M on 2022-11-22 (Series Unknown) and Turnout’s $21M on 2025-09-16 (Seed). After those, the remaining disclosed rounds drop into much smaller figures, including CeleCor Therapeutics at $3M (2022-03-08) and TradeSun at $100K (2020-12-10).
Do these Del Mar rounds cluster into a narrow date window, or are they evenly spread across time?
They cluster heavily: six of the eight rounds occur between 2022-03-08 (CeleCor Therapeutics) and 2023-04-27 (Antiva Biosciences). The other two sit in 2020, with Selva Therapeutics at $3M (2020-07-21) and TradeSun at $100K (2020-12-10).
Which sectors are over-represented among the eight entries?
Biotechnology is the most frequent sector, appearing in 3 of 8 entries: Antiva Biosciences at $53M (2023-04-27), CeleCor Therapeutics at $3M (2022-03-08), and Selva Therapeutics at $3M (2020-07-21). Health Care appears twice (SAIL Fusion $2M on 2023-04-13; Humetrix $1M on 2022-05-05), while Cloud Computing, AI, and Pharmaceutical Manufacturing appear once each.
How much of the list has non-specific or unknown round labeling?
“Series Unknown” accounts for 3 of 8 entries: SAIL Fusion ($2M, 2023-04-13), Lenz Therapeutics ($49M, 2022-11-22), and CeleCor Therapeutics ($3M, 2022-03-08). Humetrix is labeled “Venture - Series Unknown” with a $1M round on 2022-05-05, which is also effectively non-specific, making the unknown/ambiguous portion a meaningful share of the set.
Are there outliers in geography, sector, or size that stand out for deeper review?
TradeSun at $100K on 2020-12-10 is a clear size outlier compared with the rest of the disclosed amounts, which range up to $53M (Antiva Biosciences). On geography, all entries are Del Mar, but one is explicitly “Del Mar, United States” (Turnout, $21M on 2025-09-16) while the others specify “Del Mar, California,” suggesting a mostly consistent local profile rather than mixed cities.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.